Innovate

科学创新



科学创新

华夏英泰拥有完整细胞药物开发平台,满足多种临床需求

STAR-T平台

具有自主知识产权的合成性T细胞受体抗原受体( Synthetic TCR and Antigen Receptor), STAR-T细胞治疗技术平台。
与当前细胞治疗领域常用的CAR-T技术相比,STAR-T更具有天然T细胞的特性,具有天然双靶点,毒性低,耗竭慢,浸润性强的特点,更有可能实现对实体瘤治疗的突破。

enTCR-T平台

独有的enTCR-T平台包含特异化的TCR序列获取、功能验证以及多HLA型TCR-T产品制备。
突破了TCR-T特定功能性序列获取的技术瓶颈,可以快速完成针对不同人的HLA型的TCR产品开发,有望高效实现TCR-T细胞治疗的产业化。




相关新闻和发表文章

[1]A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. November 5, 2020.

了解更多ashpublications.org

[2]Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL. Hematology News. December 14, 2020.

了解更多 mdedge.com

[3]Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.Sci Transl Med. Mar 24,2021.

了解更多 pubmed.ncbi.nlm.nih.gov

[4]A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation. ASH Meeting. December 13, 2021.

了解更多 ash.confex.com

[5]A novel CD19/CD20 dual synthetic T-cell receptor and antigen receptor (STAR) T cell therapy for refractory and relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL). EHA Library.. 06/09/2021; 324526; S118.

了解更多 library.ehaweb.org

[6] A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. American Journal of Hematology.01 May 2022

了解更多 onlinelibrary.wiley.com